These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 34525199)
61. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256 [TBL] [Abstract][Full Text] [Related]
62. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model. Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896 [TBL] [Abstract][Full Text] [Related]
63. Effectiveness of a single dose of the quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, in the Korean Armed Forces. Im JH; Woo H; Ha BM; Lee JS; Chung MH; Jung J Vaccine; 2020 Jan; 38(4):730-732. PubMed ID: 31787413 [TBL] [Abstract][Full Text] [Related]
64. Emergency Meningococcal ACWY Vaccination Program for Teenagers to Control Group W Meningococcal Disease, England, 2015-2016. Campbell H; Edelstein M; Andrews N; Borrow R; Ramsay M; Ladhani S Emerg Infect Dis; 2017 Jul; 23(7):1184-1187. PubMed ID: 28409739 [TBL] [Abstract][Full Text] [Related]
65. Information needs during an emerging outbreak of meningococcal W135 disease in the Netherlands: a study among teenagers, their parents and healthcare professionals. de Vries M; Çoban FR; Claassen L; Te Wierik MJM; Timmermans DRM; Timen A BMC Public Health; 2021 Aug; 21(1):1540. PubMed ID: 34380443 [TBL] [Abstract][Full Text] [Related]
66. Analysis of meningococcal vaccine uptake in patients with invasive meningococcal disease, Czech Republic, 2006-2022. Křížová P; Okonji Z; Honskus M Epidemiol Mikrobiol Imunol; 2023; 72(4):243-247. PubMed ID: 38242709 [TBL] [Abstract][Full Text] [Related]
67. Modelling the Public Health Impact of MenACWY and MenC Adolescent Vaccination Strategies in Germany. Gruhn S; Batram M; Wick M; Langevin E; Scholz S; Greiner W; Damm O Infect Dis Ther; 2024 Apr; 13(4):907-920. PubMed ID: 38570446 [TBL] [Abstract][Full Text] [Related]
68. Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex. Stoof SP; Rodenburg GD; Knol MJ; Rümke LW; Bovenkerk S; Berbers GA; Spanjaard L; van der Ende A; Sanders EA Clin Infect Dis; 2015 Oct; 61(8):1281-92. PubMed ID: 26123933 [TBL] [Abstract][Full Text] [Related]
69. Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015. MacNeil JR; Blain AE; Wang X; Cohn AC Clin Infect Dis; 2018 Apr; 66(8):1276-1281. PubMed ID: 29126310 [TBL] [Abstract][Full Text] [Related]
70. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. De Wals P; De Serres G; Niyonsenga T JAMA; 2001 Jan; 285(2):177-81. PubMed ID: 11176810 [TBL] [Abstract][Full Text] [Related]
71. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy. Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162 [TBL] [Abstract][Full Text] [Related]
72. Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine. Watle SV; Næss LM; Tunheim G; Caugant DA; Wisløff T Hum Vaccin Immunother; 2021 Aug; 17(8):2777-2787. PubMed ID: 33631080 [TBL] [Abstract][Full Text] [Related]
73. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents. Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501 [TBL] [Abstract][Full Text] [Related]
74. Analysis of epidemiological and molecular data from invasive meningococcal disease surveillance in the Czech Republic, 1993-2020. Křížová P; Honskus M; Okonji Z; Musílek M; Kozáková J Epidemiol Mikrobiol Imunol; 2022; 71(3):148-160. PubMed ID: 36257794 [TBL] [Abstract][Full Text] [Related]
75. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults. Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449 [TBL] [Abstract][Full Text] [Related]
76. Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age. Vesikari T; Peyrani P; Webber C; Van Der Wielen M; Cheuvart B; De Schrevel N; Aris E; Cutler M; Li P; Perez JL Hum Vaccin Immunother; 2020 Jun; 16(6):1280-1291. PubMed ID: 32598244 [TBL] [Abstract][Full Text] [Related]
77. The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012. Sadarangani M; Scheifele DW; Halperin SA; Vaudry W; Le Saux N; Tsang R; Bettinger JA; Clin Infect Dis; 2014 Nov; 59(9):1208-15. PubMed ID: 25069868 [TBL] [Abstract][Full Text] [Related]
78. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD; BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030 [TBL] [Abstract][Full Text] [Related]
79. Economic evaluation on meningococcal vaccination strategies among children under nine years of age in Zhejiang province, China. Shen J; Ji C; Luo X; Hu Y PLoS One; 2024; 19(9):e0310274. PubMed ID: 39250492 [TBL] [Abstract][Full Text] [Related]
80. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT. Martinón-Torres F; Bertrand-Gerentes I; Oster P Expert Rev Vaccines; 2021 Sep; 20(9):1123-1146. PubMed ID: 34365870 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]